Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

LEGION-100

PharmaDeviceNews LEGION-100

Representative image of metastatic prostate cancer research as Syncromune’s investigational SYNC-T immunotherapy demonstrates 80% two-year survival and durable complete responses in an early Phase 1 clinical trial.

Pharma & Biotech

SYNC-T prostate cancer treatment shows encouraging long-term survival as LEGION-100 trial expands

by Soujanya Ravi
October 27, 2026
0 Comments

Syncromune's SYNC-T therapy shows 80% two-year survival in a Phase 1 metastatic prostate cancer trial. Explore results and Phase 2a plans.

Read More

Latest news and features

Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies
Tafenoquine combinations show promising parasite clearance in immunocompromised patients with babesiosis
REYOBIQ brain cancer trial: Cerenome advances targeted radiotherapy ahead of Phase 2 plans
SYNC-T prostate cancer treatment shows encouraging long-term survival as LEGION-100 trial expands
Could ATI-052 offer a new approach to asthma and eczema? Phase 1b findings support further testing
Tremont AI partners with AstraZeneca to develop AI models for preclinical drug safety assessment
Array Skin Therapy opens first Houston clinic to expand narrowband UVB treatment access
Alpheus Medical reports early LDH biomarker findings from 15-patient glioblastoma study
Orphan Therapeutics Accelerator licenses OTXL-101 gene therapy to revive development for rare paediatric disease
AbbVie submits FDA application for etentamig after Phase 3 CERVINO success in multiple myeloma
Vincora secures FDA approval for NeXuS transcatheter chordal repair feasibility study in the US
Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

POPULAR NEWS

Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.

Pharma & Biotech

Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab

October 24, 2026

Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.

Pharma & Biotech

Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study

October 24, 2026

Representative image of researchers examining Alzheimer’s disease biomarker data as NeuroSense evaluates PrimeC’s multi-target potential in a small exploratory study.

Pharma & Biotech

NeuroSense links PrimeC to Alzheimer’s biomarkers, but can three patients justify another trial?

June 26, 2026

Latest business and industry news

Anthropic warns AI could threaten humanity as $2T IPO plans reveal explosive growth and massive losses
Repligen targets up to $852m in 2026 sales as cell therapy acquisition reshapes portfolio
James Comey faces new classified information allegations, but prosecutors confront major statute-of-limitations challenge
Illinois Tool Works raises 2026 earnings outlook as record operating profit strengthens margins
HoloMD names former Eliza founder Irene Lang CEO, but can continuous AI monitoring become a scalable psychiatry business?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.